Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Rare Diseases

Carcinoma, Renal Cell

Kidney Neoplasms

Carcinoma

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Renal Cell Carcinoma

All Drugs and Chemicals

Antibodies

Vaccines

Antibodies, Bispecific

Immunoglobulins

Muromonab-CD3

Immunologic Factors

the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.

the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length\<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1

In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1

Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer

cryotherapy

Jibing Chen, Doctor

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced kidney cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for kidney cancer.

Primary kidney carcinoma is one of the most common malignancies in China,immunotherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single- center, The investigators plan to recruit for 90 patients with advanced kidney cancer,and all patients are divided into three groups.one group will receive cryotherapy, one group will receive conventional therapy，and the rest one will receive mixed liquor of activated CIK and anti-CD3-MUC1 bispecific antibody together with cryotherapy.

The result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard.

This is a phase II clinical trial of single-center, and it will divide into three groups.

With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were assigned to three groups,receive cryotherapy,conventional therapy, and activated CIK armed with anti-CD3-MUC1 bispecific antibody together with cryotherapy .every participant has a unique identification number and emergency letter which have the information of group.

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer

Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Kidney Cancer

ORR.The proportion of patients who had a best response rating of complete response and partial response.

PFS.The time of patients from randomization to death caused by the progression of the tumor or any cause.

TTP.The time of patient from randomization to objective progress of the tumor.

DCR.The proportion of patients who had a best response rating of complete response, partial response,or stable disease.

OS.The time of patient from randomization to death caused by any cause

SRR. The proportion of symptoms are alleviated in all evaluative cases.

Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.

Fuda Cancer Hospital, Guangzhou

Digestive System Diseases

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Hematinics

Liver Extracts

Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced liver cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for liver cancer.

Primary hepatocellular carcinoma is one of the most common malignancies in China, ranking fourth in all malignant tumors and third in mortality.immunotherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single- center, The investigators plan to recruit for 90 patients with advanced liver cancer,and all patients are divided into three groups.one group will receive cryotherapy, one group will receive Non-intervention therapy，and the rest one will receive mixed liquor of activated CIK and anti-CD3-MUC1 bispecific antibody together with cryotherapy.

The result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard.

With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were assigned to three groups,receive cryotherapy,non-intervention therapy, and activated CIK armed with anti-CD3-MUC1 bispecific antibody together with cryotherapy .every participant has a unique identification number and emergency letter which have the information of group.

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer

Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Liver Cancer

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced breast cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for breast cancer.

Primary breast carcinoma is one of the most common malignancies in China, ranking first in all malignant tumors of women.immunotherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single- center, The investigators plan to recruit for 90 patients with advanced breast cancer,and all patients are divided into three groups.one group will receive cryotherapy, one group will receive conventional therapy，and the rest one will receive mixed liquor of activated CIK and anti-CD3-MUC1 bispecific antibody together with cryotherapy.

The result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard.

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer

Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Breast Cancer

Gland and Hormone Related Diseases

Pancreatic Neoplasms

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced pancreatic cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for pancreatic cancer.

Primary pancreatic carcinoma is one of the most common malignancies in China, immunotherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single- center, The investigators plan to recruit for 90 patients with advanced pancreatic cancer,and all patients are divided into three groups.one group will receive cryotherapy, one group will receive conventional therapy，and the rest one will receive mixed liquor of activated CIK and anti-CD3-MUC1 bispecific antibody together with cryotherapy.

The result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer	NCT03540199	Advanced Kidney...	Activated CIK a... cryotherapy	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer	NCT03540199	Advanced Kidney...	Activated CIK a... cryotherapy	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer	NCT03484962	Advanced Liver ...	Activated CIK a... cryotherapy	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer	NCT03484962	Advanced Liver ...	Activated CIK a... cryotherapy	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer	NCT03524261	Advanced Breast...	Activated CIK a... cryotherapy	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer	NCT03509298	Advanced Pancre...	Activated CIK a... cryotherapy	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou

Spots Global Cancer Trial Database for activated cik